Novartis Ag

Clive Victor Walker

Darren Mark Le Grand

Keith Allan Menear

Stephen Paul Collingwood

Clive McCarthy

Gurdip Bhalay

Xiao-Ling Fan Cockcroft

Henri Mattes

Judy Fox Hayler

John James Woods

Compounds of formula I in free or salt form, wherein Ar, X, Y, R, R, R, R, m, n, p and q have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Azetidine derivatives as CCR-3 receptor antagonists

This invention relates to organic compounds of formula I, in which Aris unsubstituted phenyl substituted by one or more halogen atoms; Aris unsubstituted phenyl or phenyl substituted by one or more substituents selected from the group consisting of halogen, cyano and C-C-alkoxy; Ris hydrogen or methyl optionally substituted by hydroxy; Ris hydrogen or hydroxy; and pharmaceutically acceptable salts thereof. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.

Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions

Purine derivatives inhibitors of tyrosine protein kinase SYK

Growing community of inventors

Horsham, United Kingdom

Clive Victor Walker